Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection-Reference-Cited by-同舟云学术

Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection

Author:

Carter Lukas M.¹,Poty Sophie¹^ORCID,Sharma Sai Kiran¹^ORCID,Lewis Jason S.¹²³⁴^ORCID

Affiliation:

1. Department of Radiology; Memorial Sloan Kettering Cancer Center; New York New York USA

2. Molecular Pharmacology Program; Memorial Sloan Kettering Cancer Center; New York New York USA

3. Departments of Radiology and Pharmacology; Weill Cornell Medical College; New York New York USA

4. Radiochemistry and Molecular Imaging Probes Core; Memorial Sloan Kettering Cancer Center; New York New York USA

Funder

Ruth L. Kirschstein Postdoctoral Fellowship

Tow Postdoctoral Fellowship

National Institutes of Health

Publisher

Wiley

Subject

Organic Chemistry,Spectroscopy,Drug Discovery,Radiology, Nuclear Medicine and imaging,Biochemistry,Analytical Chemistry

Reference140 articles.

4. Engineering antibody therapeutics;Chiu;Curr Opin Struct Biol,2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

4. Cadherin-17 as a target for the immunoPET of adenocarcinoma;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-16